https://orcid.org/0000-0001-8627-1263
References
- Zeng Q-L, Zhou Y-H. Requirement for further validation on the seroconversion of hepatitis B surface antigen in successful vaccines. Hum Vaccin Immunother. In press;2021:1–7.
- Wang F, Shen LP, Cui FQ, Zhang S, Zheng H, Zhang Y, Liang X, Wang F, Bi S. The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China[J]. Vaccine. 2015;33(23):2704–09. doi:10.1016/j.vaccine.2015.03.064.
- Gong J, Li RC, Yang JY, Li YP, Chen XR, Xu ZY, Liu CB, Cao HL, Zhao K, Ni DM. Long-term efficacy of infant hepatitis B immunization program. Chin J Hepatol. 2003;11:203–05.
- Shen LP, Yang JY, Mo ZJ, Li RC, Li YP, Wei ZL, Dong YH, Zhou KJ, Wei SC, Fang KX, et al. Variation of hepatitis B virus infection epidemic pattern after long term HBV vaccine immunization. Chin J of Exp Clin Virol. 2007 Sep;21(3):253–55.
- Li H, Li GJ, Chen QY, Fang ZL, Wang XY, Tan C, Yang QL, Wang FZ, Wang F, Zhang S, et al. Long-term effectiveness of plasma-derived hepatitis B vaccine 22–28 years after immunization in a hepatitis B virus endemic rural area: is an adult booster dose needed? Life history traits of the higher trophic level parasitoid Meteorus pulchricornis (Hymenoptera: braconidae). Epidemiol Infect. 2017:1–8. © Cambridge University Press. doi:10.1017/S0950268816003046.
- Cui F, Shen L, Li L, Wang H, Wang F, Bi S, Liu J, Zhang G, Wang F, Zheng H, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017;23(5):765–72. doi:10.3201/eid2305.161477.
- Zheng Z, Li G, Liao F, Zhang L, Wang X, Fang Z, Chen Q, Liu H, Hu L. Seroconversion of hepatitis B surface antigen among those with previously successful immune response in Southern China. Hum Vaccin Immunother. 2020 Sep;22:1–7. doi:10.1080/21645515.2020.1801076.
- Coppola N, Loquercio G, Tonziello G, Azzaro R, Pisaturo M, Di Costanzo G, Starace M, Pasquale G, Cacciapuoti C, Petruzziello A. HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol PMID:23856167. 2013;58(1):315–17. doi:10.1016/j.jcv.2013.06.020.
- Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, Thomas H, Zuckerman AJ. Hepatitis B variant in Europe. Lancet PMID:2460710. 1988;2:1132–33. doi:10.1016/S0140-6736(88)90541-7.